Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
Ipilimumab/nivolumab demonstrated a significantly longer OS at the 12-month milestone and an acceptable toxicity profile. Our results therefore underline a relevant clinical benefit of ipilimumab/nivolumab in previously untreated nccRCC entities compared to current SOC.
Authors
- Aude Fléchon (ORCID: https://orcid.org/0000-0002-0129-6101)
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Marc‐Oliver Grimm (ORCID: https://orcid.org/0000-0003-3084-8654)
- Begoña Mellado (ORCID: https://orcid.org/0000-0002-8088-5966)
- Franck Priou
- Ekaterini Boleti
- Marine Gross‐Goupil (ORCID: https://orcid.org/0000-0002-3176-4076)
- J.B.A.G. Haanen
- Stefan Siemer (ORCID: https://orcid.org/0000-0001-7670-8644)
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Philipp Ivanyi (ORCID: https://orcid.org/0000-0002-2862-7302)
- Sjoukje F. Oosting (ORCID: https://orcid.org/0000-0003-2754-6997)
- Philippe Barthélémy (ORCID: https://orcid.org/0000-0003-3917-0579)
- Stefanie Zschäbitz (ORCID: https://orcid.org/0000-0001-8917-3263)
- Pablo Maroto (ORCID: https://orcid.org/0000-0002-0030-0412)
- Florence Joly (ORCID: https://orcid.org/0000-0001-6168-4942)
- Sylvie Rottey (ORCID: https://orcid.org/0000-0003-2060-3725)
- Marit Ahrens (ORCID: https://orcid.org/0000-0003-4313-0895)
- Jindřich Kopecký (ORCID: https://orcid.org/0000-0002-4126-0410)
- Arndt Hartmann (ORCID: https://orcid.org/0000-0002-4860-4626)
- Dorothee Deckbar
- M. Retz
- Anne Flörcken
- Gwénaëlle Gravis (ORCID: https://orcid.org/0000-0002-3127-1554)
- Laurence Albigès (ORCID: https://orcid.org/0000-0002-5734-3480)
- Cristina Suárez (ORCID: https://orcid.org/0000-0002-0502-5528)
- Jens Bedke (ORCID: https://orcid.org/0000-0003-2778-3108)
- Tomáš Büchler (ORCID: https://orcid.org/0000-0001-6667-994X)
- Peter J. Goebell (ORCID: https://orcid.org/0000-0003-0176-4478)
- Günter Niegisch (ORCID: https://orcid.org/0000-0001-6929-8691)
- Tom Waddell (ORCID: https://orcid.org/0000-0001-5652-3829)
- L. Bergmann
- Martin Boegemann
- U. Zimmermann
- Iris Burkholder
Institutions
- Goethe University Frankfurt (DE)
- Hebron University (PS)
- Centre National de la Recherche Scientifique (FR)
- University Medical Center Groningen (NL)
- Inserm (FR)
- Royal Free London NHS Foundation Trust (GB)
- University of Groningen (NL)
- Fulda University of Applied Sciences (DE)
- Charles University (CZ)
- Heidelberg University (DE)
- Universitätsmedizin Greifswald (DE)
- Ghent University Hospital (BE)
- Hospital de Sant Pau (ES)
- Institut Gustave Roussy (FR)
- University Hospital Heidelberg (DE)
- TUM Klinikum (DE)
- The Netherlands Cancer Institute (NL)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Medizinische Hochschule Hannover (DE)
- Humboldt-Universität zu Berlin (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- Institut de Cancérologie Strasbourg (FR)
- University Hospital Münster (DE)
- Centre Léon Bérard (FR)
- Immunité et Cancer (FR)
- Oncode Institute (NL)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario HM Madrid (ES)
- Essen University Hospital (DE)
- Centre François Baclesse (FR)
- Vall d'Hebron Hospital Universitari (ES)
- University Hospital Frankfurt (DE)
- The Christie NHS Foundation Trust (GB)
- Jena University Hospital (DE)
- University Hospital Hradec Králové (CZ)
- Thomayer University Hospital (CZ)
- Centre Hospitalier Départemental Vendée (FR)
- Comprehensive Cancer Center Erlangen (DE)
- Klinikum Stuttgart (DE)
- Heinrich Heine University Düsseldorf (DE)
- Technical University of Munich (DE)
- University of Tübingen (DE)
- Saarland University (DE)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.annonc.2025.03.016
- Citations
- 29
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 44.03
Funders
- Bristol-Myers Squibb
- Clinical Trial Center, China Medical University Hospital
- European Society for Medical Oncology
- AIO-Studien